Epichem CEO, Colin La Galia, resigns

PERTH, AUSTRALIA: PharmAust Limited (ASX: PAA & PAAO), a clinical stage biotechnology company, announced that Colin La Galia, Chief Executive Officer (CEO) of PAA’s subsidiary Epichem, has resigned.

La Galia will leave Epichem on 23 March 2022 to pursue another opportunity based in Perth. That business is not a competitor to Epichem or PharmAust.

PharmAust and Mr La Galia have agreed that he will continue to provide strategic and operational input into the Epichem business as a consultant beyond 23 March.

Epichem has commenced an executive search for a General Manager and also a new business development executive.

Head of Chemistry Dr Gary Pitt will be responsible for the DNDi contract and oversees all medicinal and synthetic chemistry projects. Head of Production Dr James Rixson is responsible for the OHD project, reference materials, catalogue synthesis and custom synthesis. Dr Carol Worth will oversee analytical services and quality management.

Colin La Galia joined Epichem in 2019 and grew the business by driving performance and developing people. He leaves the organisation with a number of achievements including signing a number of new national and global medicinal and synthetic clients and projects, his focus on the development of new IP R&D projects and several State and national awards.

His tenure was also marked by adoption and development of the innovative waste conversion and re-purposing technology, Oxidative Hydrothermal Dissolution (OHD); employment opportunities for PhD chemists; and exports to more than 40 countries.

PharmAust’s Executive Chair Dr Roger Aston said, “We are very pleased at what Colin achieved and he leaves the Epichem business well positioned for further growth led by its strong executive team. We wish Colin well and are delighted he will remain involved as a consultant to the Epichem business.”

Mr Colin La Galia said, “I am very proud of what I and my team achieved at Epichem and believe the organization is now in a much stronger and sustainable position. The DNDi contract for 2022 has been secured for a 14th consecutive year and the pipeline of works in medicinal and synthetic chemistry is healthy.


About the author

Leave a Reply

Your email address will not be published.